ZAMUDIO, Spain--(

ZAMUDIO, 西班牙--(

BUSINESS WIRE

商业热线

)--ONCOMATRYX, a biopharmaceutical company developing novel ADCs against the tumor microenvironment, has successfully raised €25 million, to fund Phase Ib-II clinical trials of OMTX705, a first-in-class ADC targeting FAP.

)--ONCOMATRYX是一家开发针对肿瘤微环境的新型ADC的生物制药公司，已成功筹集2500万欧元，用于资助OMTX705的Ib II期临床试验，OMTX705是针对FAP的一流ADC。

The funding round was led by the company’s existing investors and included a €10 million strategic investment from

这轮融资由该公司现有投资者牵头，其中包括1000万欧元的战略投资

Centro para el Desarrollo Tecnológico y la Innovación.

技术发展和创新中心。

This endorsement highlights the confidence in ONCOMATRYX pioneering ADCs to treat metastatic solid tumors.

这一认可突显了对ONCOMATRYX开创性ADC治疗转移性实体瘤的信心。

“We are thrilled to count on the continued support of our existing investors and welcome CDTI through Innvierte, an investment program of CDTI” said Dr. Laureano Simon, CEO of ONCOMATRYX. “This funding validates our clinical progress and equips us to execute on critical milestones and deliver transformative therapies to patients.”.

ONCOMATRYX首席执行官Laureano Simon博士表示：“我们很高兴能够继续得到现有投资者的支持，并通过CDTI的投资项目Innvierte欢迎CDTI。”。“这笔资金验证了我们的临床进展，使我们能够执行关键的里程碑，并为患者提供变革性治疗。”。

About Oncomatryx

About Oncomatryx

Oncomatryx has developed a proprietary Antibody-Drug Conjugates platform that targets Cancer-Associated Fibroblasts in the microenvironment of metastatic solid tumors.

Oncomatryx开发了一种专有的抗体-药物偶联物平台，可靶向转移性实体瘤微环境中与癌症相关的成纤维细胞。

Oncomatryx pioneering ADCs against immunosuppressive CAFs are developed in collaboration with prestigious universities, hospitals and research centers in USA and Europe.

Oncomatryx开创性的针对免疫抑制性CAF的ADC是与美国和欧洲的著名大学，医院和研究中心合作开发的。

Phase I clinical results of OMTX705, a novel ADC targeting Fibroblast Activation Protein in the Cancer-Associated Fibroblasts, will be presented at major Oncology conferences along 2025.

OMTX705是一种针对癌症相关成纤维细胞中成纤维细胞活化蛋白的新型ADC，其I期临床结果将在2025年的主要肿瘤学会议上发表。

https://clinicaltrials.gov/ct2/show/NCT05547321?term=oncomatryx&draw=2&rank=1

https://clinicaltrials.gov/ct2/show/NCT05547321?term=oncomatryx&draw=2&rank=1

For more information and updates about Oncomatryx and its clinical programs, please contact: